Business
PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market
NEWPORT BEACH, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company,” “PMGC,” “us,” or “we”) (Nasdaq:ELAB), a diversified holding
About this update from Pmgc Holdings Inc.
[{"type":"text","content":"NEWPORT BEACH, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company,” “PMGC,” “us,” or “we”) (Nasdaq:ELAB), a diversified holding company, today announced an update on its capital structure, highlighting its financial position and ongoing commitment to executing its strategic priorities through its operating subsidiaries. As of February 25, 2025, PMGC’s capital structure is as follows: Common Shares Outstanding: 4,042,295.Stock Options Outstanding: 4,931 shares of Common Stock issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $304 per share.Warrants Outstanding: 979,814 shares of Common Stock issuable upon the exercise of outstanding warrants with a weighted-average exercise price of $4.91 per share, including: 969,386 shares issuable upon the exercise of warrants with an exercise price of $2.75 per share.All warrants are standard, “plain vanilla” warrants with no ratchet provisions. Debt: The Company has zero debt.Short Interest: As of January 31, 2025, the short interest in the Company was 334,969 shares, according to The Nasdaq Stock Market LLC. Recent Capital Raises September 2024 – The Company raised $8.0 million in gross proceeds via an S-1 offering of common stock, pre-funded warrants and Series A and Series B warrants. All warrants associated with this raise have been exercised. Filing here: XBRL ViewerJanuary 2025 – The Company received approximately $1.9 million in gross proceeds via a warrant inducement offering with certain institutional investors. Filing here: Inline Viewer: PMGC Holdings Inc. 8-K 2025-01-27 PMGC believes it currently has a strong capital position and is poised to continue executing its strategic priorities through its operating subsidiaries, set forth below: NorthStrive Biosciences Inc. – A biopharmaceutical company focused on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, leverages an engineered probiotic approach to address a pressing issue in the obesity market, preserving muscle in patients undergoing weight loss treatments, including GLP-1 receptor agonists. For more information, visit northstrivebio.com.PMGC Research Inc. – A research and development subsidiary which utilizes Canadian research grants and partners with leading Canadian universities to accelerate scientific discove...